Delivery Order SPE2DB24D1021-SPE2DB25FEZZK
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,577.14 to AmerisourceBergen Drug Corp for the supply of CellCept 250 mg capsules (100 count) on August 13, 2025, with an ultimate completion date of August 14, 2025. This competitively awarded, firm fixed-price delivery order was issued without set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. CellCept (mycophenolate mofetil) is an immunosuppressant medication commonly...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, received a delivery order award from the Defense Logistics Agency (DLA) on July 16, 2025, for CellCept 250 mg capsules (100-count units) with a ceiling value of $17,152.58. This firm fixed-price delivery order, which is due for completion by July 17, 2025, represents a non-set-aside competitive award under the broader pharmaceutical supply framework. The contract will be performed at AmerisourceBergen's corporate office...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 100 tablets of CellCept 500 mg on August 25, 2025, with a ceiling value of $2,407.68 and a firm fixed price structure. This is a non-set-aside, competitively awarded contract with a place of performance in Conshohocken, Pennsylvania, and an ultimate completion date of August 26, 2025. The delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with DLA Troop Support...
- AmerisourceBergen Drug Corp has been awarded a delivery order by the Defense Logistics Agency (DLA) for CellCept 500 mg tablets (100 count) valued at $1,283.84, with an award date of August 13, 2025, and ultimate completion by August 14, 2025. This firm fixed-price, non-set-aside delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive $999.99 billion pharmaceutical supply vehicle running through...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on April 28, 2025, for the supply of CellCept 500 mg tablets (100-count units) with a ceiling value of $2,407.68. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under open competition. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, with an ultimate completion date of April 29, 2025. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order valued at $3,508.35 to AmerisourceBergen Drug Corp for 100 capsules of CellCept 250 mg, an immunosuppressant medication commonly used in transplant and autoimmune disease management. This firm fixed-price delivery order, awarded on October 27, 2025, with an ultimate completion date of October 28, 2025, represents a competitively awarded contract with no set-aside designation. The pharmaceutical will be delivered to Conshohocken, Pennsylvania,...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a competitively awarded delivery order (Contract No. 4568982464) by the Defense Logistics Agency on August 4, 2025, for the supply of CellCept 500 mg tablets in a quantity of 100 units. This firm fixed-price delivery order carries a ceiling value of $7,817.19 and is scheduled for ultimate completion by August 5, 2025. The contract carries no set-aside designation and will be...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of CellCept 500 mg tablets (100-count packages) under a firm fixed-price contract valued at $4,349.15. This is a non-set-aside competitive award with an ultimate completion date of August 26, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 500 mg CellCept tablets (500-count units) valued at $44,285.82 with a firm fixed price structure. The delivery order, issued on September 25, 2025, with an ultimate completion date of September 26, 2025, represents a competitive award with no set-aside designation. Performance will be executed at the contractor's Conshohocken, Pennsylvania location, which serves as the company's corporate headquarters and...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of CellCept 500 mg tablets (100 count) on September 8, 2025, with an ultimate completion date of September 9, 2025. This competitively awarded, firm fixed-price delivery order has a ceiling value of $27,735.62 and carries no set-aside designation. The order will be fulfilled from the vendor's Conshohocken, Pennsylvania location, where AmerisourceBergen maintains its corporate headquarters as a...
- SPE2DB24D1021Indefinite Delivery Contract
- SPE2DB24D1021-SPE2DB25FEZZKDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for CellCept 250 mg capsules (100-count units) with a ceiling value of $1,382.42. The contract, executed on August 25, 2025, with an ultimate completion date of August 26, 2025, is structured as a firm fixed-price delivery order with no set-aside designation. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $1 billion prime vendor contract valued through December 2026 that enables the company to supply pharmaceutical products and medical supplies to support military healthcare programs globally. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical federal medical procurement vendor for military and veteran healthcare systems. The company has demonstrated capability to fulfill federal requirements through competitive award processes, with its federal contract portfolio spanning a comprehensive range of pharmaceutical products including specialty medications, brand-name and generic drugs, and medical supplies. CellCept (mycophenolate mofetil) is an immunosuppressant medication commonly used in military medical settings for transplant recipients and patients with autoimmune conditions, making this delivery order consistent with the Defense Health Agency's pharmaceutical supply requirements through the DLA's medical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.4k | 8/25/25 |